ArticleScientific reports2025
Prognostic significance of clinicopathological and ultrasonographic features in anaplastic thyroid carcinoma beyond TERT promoter mutation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Convergent Mechanistic Pathways Driving the Anaplastic Phenotype in Thyroid Cancer.International journal of molecular sciences · 2026Review
- HighCancers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
TERT promoter mutation is associated with poor prognosis in differentiated thyroid carcinoma, with US features varying by mutation status. However, this correlation in anaplastic thyroid carcinoma (ATC) is understudied. We investigated the association between clinicopathological characteristics and US features of ATC with TERT mutation status and prognosis. From November 1994 to May 2022, 58 ATC nodules from 58 patients were analyzed. Two radiologists retrospectively reviewed US features based on the revised K-TIRADS and ACR-TIRADS. Of all 58 ATC nodules, 32 nodules were tested for TERT promoter mutation and detected in 11. TERT promoter-mutated ATC was larger than TERT wild-type ATC (p = 0.032); however, no other differences were observed. ATC with survival period of less than 12 months were more likely to have lymph node metastasis (p = 0.012) or distant metastasis at diagnosis (p < 0.001), larger size on US (p = 0.005), and suspicion for gross extrathyroidal extension on US (p = 0.04) compared to ATC with survival period of 12 months or more. Advanced disease at diagnosis was a critical factor associated with 1-year survival in patients with ATC, whereas the TERT promoter mutation status was not.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.